NetScientific plc Director/PDMR Shareholding NetScientific plc (AIM:NSCI) (the “Company”), the transatlantic healthcare IP commercialisation group, announced on 22 June 2022, that it had closed its Placing of 2,238,807 Placing Shares at a Placing Price of 67 pence per Placing Share. Dr Ilian Iliev and Mr John Clarkson (each a Director of the Company) and Mr Stephen Crowe (CFO) each participated in the…
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: NetScientific Plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with…
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR…
THE INFORMATION IN THIS ANNOUNCEMENT, WHICH INCLUDES CERTAIN INFORMATION DRAWN FROM PUBLIC SOURCES, DOES NOT PURPORT TO BE COMPREHENSIVE AND HAS NOT BEEN INDEPENDENTLY VERIFIED. THIS ANNOUNCEMENT CONTAINS STATEMENTS THAT ARE, OR MAY BE DEEMED, FORWARD-LOOKING STATEMENTS, WHICH RELATE, INTER ALIA, TO THE COMPANY'S PROPOSED STRATEGY, PLANS AND OBJECTIVES. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER IMPORTANT FACTORS BEYOND THE…
RNS REACH NetScientific plc ("NetScientific", the "Group" or the "Company") NetScientific to increase Q-Bot stake to 23.7% NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group announces that EMV Capital, its wholly-owned subsidiary, has agreed to acquire (either itself or using a nominee) a further stake in Q-Bot of 1,066 ordinary shares (3.13%) for a total consideration of…
NetScientific plc (“NetScientific”, the “Group” or the “Company”) Q-Bot Limited (“Q-Bot”) secures £1.6m of investment to fund growth NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group announces that portfolio company Q-Bot has successfully closed a £1.62m investment round to fund the next stage of its growth. The additional funds will allow Q-Bot to accelerate the rollout…
NetScientific plc (“NetScientific” or the “Company”) Notice of AGM and Annual Report & Accounts London, UK – 07 June 2022 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation group, announces that in accordance with AIM Rules 20 and 26 the Group’s Annual Report and Accounts for the year ended 31 December 2021 and Notice of…
06 June 2022 NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101 NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has been granted Fast Track designation for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech presents new data for two ongoing clinical trials NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has provided updates for two their ongoing Phase 2 clinical trials, ahead of presentations at the ASCO 2022 oncology research…
NetScientific plc (“NetScientific” or the “Company”) General Counsel Strategic Hire and Grant of Options NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation group, is delighted to announce the appointment of its first General Counsel, Ed Hooper, with immediate effect. Ed also joins as Group Company Secretary and as Executive Director to the Company's corporate finance specialist subsidiary,…
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.